Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2002 Apr;57(4):323–327. doi: 10.1136/thorax.57.4.323

Role of cysteinyl leukotrienes in adenosine 5`-monophosphate induced bronchoconstriction in asthma

S Rorke 1, S Jennison 1, J Jeffs 1, A Sampson 1, H Arshad 1, S Holgate 1
PMCID: PMC1746289  PMID: 11923550

Abstract

Background: Adenosine induced bronchoconstriction in patients with asthma is thought to be mediated by the synthesis and release of autacoids from airway mast cells. In vitro, adenosine induced constriction of asthmatic bronchi is blocked by a combination of specific histamine and cysteinyl leukotriene receptor antagonists, but the relative contribution of these mediators in vivo is unclear. We hypothesised that adenosine induced bronchoconstriction in asthmatic patients may be blocked by pretreatment with the orally active selective cysteinyl leukotriene-1 (CysLT1) receptor antagonist, montelukast.

Methods: In a randomised, double blind, crossover study, oral montelukast (10 mg) or placebo was administered once daily on two consecutive days to 18 patients with mild to moderate persistent atopic asthma. Incremental doses of adenosine 5`-monophosphate (AMP) from 0.39 to 400 mg/ml were inhaled by dosimeter and the dose producing a 20% fall in FEV1 (PC20AMP) after AMP inhalation was recorded. Leukotriene E4 (LTE4) urinary concentrations were measured by enzyme immunoassay 4 hours after AMP challenge.

Results: Montelukast pretreatment provided highly significant protection against adenosine induced bronchoconstriction, with geometric mean PC20AMP values of 52.6 mg/ml (95% CI 35.2 to 78.7) after placebo and 123.9 mg/ml (95% CI 83.0 to 185.0) after montelukast (p=0.006). The geometric mean of the montelukast/placebo PC20AMP ratio was 2.4 (95% CI 1.3 to 4.2). Montelukast had no significant effect on 4 hour urinary excretion of LTE4 compared with placebo.

Conclusions: Selective CysLT1 receptor antagonism with montelukast provides highly significant protection against AMP induced bronchoconstriction in patients with atopic asthma, implying that cysteinyl leukotrienes are generated from airway mast cells through preferential activation of their A2B receptors.

Full Text

The Full Text of this article is available as a PDF (161.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Björck T., Gustafsson L. E., Dahlén S. E. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis. 1992 May;145(5):1087–1091. doi: 10.1164/ajrccm/145.5.1087. [DOI] [PubMed] [Google Scholar]
  2. Christie P. E., Tagari P., Ford-Hutchinson A. W., Charlesson S., Chee P., Arm J. P., Lee T. H. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991 May;143(5 Pt 1):1025–1029. doi: 10.1164/ajrccm/143.5_Pt_1.1025. [DOI] [PubMed] [Google Scholar]
  3. Crimi N., Palermo F., Polosa R., Oliveri R., Maccarrone C., Palermo B., Mistretta A. Effect of indomethacin on adenosine-induced bronchoconstriction. J Allergy Clin Immunol. 1989 May;83(5):921–925. doi: 10.1016/0091-6749(89)90106-1. [DOI] [PubMed] [Google Scholar]
  4. Cushley M. J., Tattersfield A. E., Holgate S. T. Adenosine-induced bronchoconstriction in asthma. Antagonism by inhaled theophylline. Am Rev Respir Dis. 1984 Mar;129(3):380–384. doi: 10.1164/arrd.1984.129.3.380. [DOI] [PubMed] [Google Scholar]
  5. Cushley M. J., Tattersfield A. E., Holgate S. T. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol. 1983 Feb;15(2):161–165. doi: 10.1111/j.1365-2125.1983.tb01481.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dahlén S. E., Hansson G., Hedqvist P., Björck T., Granström E., Dahlén B. Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. Proc Natl Acad Sci U S A. 1983 Mar;80(6):1712–1716. doi: 10.1073/pnas.80.6.1712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Drazen J. M., Israel E., O'Byrne P. M. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999 Jan 21;340(3):197–206. doi: 10.1056/NEJM199901213400306. [DOI] [PubMed] [Google Scholar]
  8. Feoktistov I., Polosa R., Holgate S. T., Biaggioni I. Adenosine A2B receptors: a novel therapeutic target in asthma? Trends Pharmacol Sci. 1998 Apr;19(4):148–153. doi: 10.1016/s0165-6147(98)01179-1. [DOI] [PubMed] [Google Scholar]
  9. Finnerty J. P., Polosa R., Holgate S. T. Repeated exposure of asthmatic airways to inhaled adenosine 5'-monophosphate attenuates bronchoconstriction provoked by exercise. J Allergy Clin Immunol. 1990 Sep;86(3 Pt 1):353–359. doi: 10.1016/s0091-6749(05)80098-3. [DOI] [PubMed] [Google Scholar]
  10. Finnerty J. P., Wood-Baker R., Thomson H., Holgate S. T. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):746–749. doi: 10.1164/ajrccm/145.4_Pt_1.746. [DOI] [PubMed] [Google Scholar]
  11. Forsythe P., Ennis M. Adenosine, mast cells and asthma. Inflamm Res. 1999 Jun;48(6):301–307. doi: 10.1007/s000110050464. [DOI] [PubMed] [Google Scholar]
  12. Hughes P. J., Holgate S. T., Church M. K. Adenosine inhibits and potentiates IgE-dependent histamine release from human lung mast cells by an A2-purinoceptor mediated mechanism. Biochem Pharmacol. 1984 Dec 1;33(23):3847–3852. doi: 10.1016/0006-2952(84)90050-9. [DOI] [PubMed] [Google Scholar]
  13. In K. H., Asano K., Beier D., Grobholz J., Finn P. W., Silverman E. K., Silverman E. S., Collins T., Fischer A. R., Keith T. P. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest. 1997 Mar 1;99(5):1130–1137. doi: 10.1172/JCI119241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Israel E., Dermarkarian R., Rosenberg M., Sperling R., Taylor G., Rubin P., Drazen J. M. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med. 1990 Dec 20;323(25):1740–1744. doi: 10.1056/NEJM199012203232505. [DOI] [PubMed] [Google Scholar]
  15. Israel E., Fischer A. R., Rosenberg M. A., Lilly C. M., Callery J. C., Shapiro J., Cohn J., Rubin P., Drazen J. M. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1447–1451. doi: 10.1164/ajrccm/148.6_Pt_1.1447. [DOI] [PubMed] [Google Scholar]
  16. Kumlin M., Stensvad F., Larsson L., Dahlén B., Dahlén S. E. Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans. Clin Exp Allergy. 1995 May;25(5):467–479. doi: 10.1111/j.1365-2222.1995.tb01079.x. [DOI] [PubMed] [Google Scholar]
  17. Lazarus S. C., Wong H. H., Watts M. J., Boushey H. A., Lavins B. J., Minkwitz M. C. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med. 1997 Dec;156(6):1725–1730. doi: 10.1164/ajrccm.156.6.9608006. [DOI] [PubMed] [Google Scholar]
  18. Lynch K. R., O'Neill G. P., Liu Q., Im D. S., Sawyer N., Metters K. M., Coulombe N., Abramovitz M., Figueroa D. J., Zeng Z. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999 Jun 24;399(6738):789–793. doi: 10.1038/21658. [DOI] [PubMed] [Google Scholar]
  19. Peachell P. T., Columbo M., Kagey-Sobotka A., Lichtenstein L. M., Marone G. Adenosine potentiates mediator release from human lung mast cells. Am Rev Respir Dis. 1988 Nov;138(5):1143–1151. doi: 10.1164/ajrccm/138.5.1143. [DOI] [PubMed] [Google Scholar]
  20. Phillips G. D., Polosa R., Holgate S. T. The effect of histamine-H1 receptor antagonism with terfenadine on concentration-related AMP-induced bronchoconstriction in asthma. Clin Exp Allergy. 1989 Jul;19(4):405–409. doi: 10.1111/j.1365-2222.1989.tb02406.x. [DOI] [PubMed] [Google Scholar]
  21. Phillips G. D., Rafferty P., Beasley R., Holgate S. T. Effect of oral terfenadine on the bronchoconstrictor response to inhaled histamine and adenosine 5'-monophosphate in non-atopic asthma. Thorax. 1987 Dec;42(12):939–945. doi: 10.1136/thx.42.12.939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Polosa R., Holgate S. T. Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma? Thorax. 1997 Oct;52(10):919–923. doi: 10.1136/thx.52.10.919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rafferty P., Beasley R., Holgate S. T. The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5' monophosphate in atopic asthma. Am Rev Respir Dis. 1987 Aug;136(2):369–373. doi: 10.1164/ajrccm/136.2.369. [DOI] [PubMed] [Google Scholar]
  24. Sampson A. P., Siddiqui S., Buchanan D., Howarth P. H., Holgate S. T., Holloway J. W., Sayers I. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax. 2000 Oct;55 (Suppl 2):S28–S31. doi: 10.1136/thorax.55.suppl_2.S28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Taylor G. W., Taylor I., Black P., Maltby N. H., Turner N., Fuller R. W., Dollery C. T. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet. 1989 Mar 18;1(8638):584–588. doi: 10.1016/s0140-6736(89)91611-5. [DOI] [PubMed] [Google Scholar]
  26. Van Schoor J., Joos G. F., Kips J. C., Drajesk J. F., Carpentier P. J., Pauwels R. A. The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med. 1997 Mar;155(3):875–880. doi: 10.1164/ajrccm.155.3.9117020. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES